Stephen Silvestro Sells 1,620 Shares of OptimizeRx (NASDAQ:OPRX) Stock

OptimizeRx Corp. (NASDAQ:OPRX) CEO Stephen Silvestro sold 1,620 shares of OptimizeRx stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $18.75, for a total transaction of $30,375.00. Following the sale, the chief executive officer directly owned 188,916 shares in the company, valued at $3,542,175. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

OptimizeRx Stock Performance

OptimizeRx stock opened at $18.24 on Thursday. OptimizeRx Corp. has a 12-month low of $3.78 and a 12-month high of $20.69. The company has a market capitalization of $338.72 million, a price-to-earnings ratio of -33.78 and a beta of 1.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. The firm’s fifty day moving average price is $17.24 and its 200 day moving average price is $13.36.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC boosted its holdings in shares of OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after buying an additional 1,818 shares during the period. Quantbot Technologies LP acquired a new position in shares of OptimizeRx in the 2nd quarter valued at about $44,000. GAMMA Investing LLC acquired a new position in shares of OptimizeRx in the 1st quarter valued at about $33,000. BNP Paribas Financial Markets boosted its holdings in shares of OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after buying an additional 2,215 shares during the period. Finally, Corton Capital Inc. acquired a new position in shares of OptimizeRx in the 2nd quarter valued at about $138,000. 76.47% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on OPRX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of OptimizeRx in a research report on Wednesday. Stifel Nicolaus boosted their target price on shares of OptimizeRx from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Zacks Research raised shares of OptimizeRx from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 5th. Roth Capital reissued a “buy” rating on shares of OptimizeRx in a research report on Friday, August 8th. Finally, JMP Securities boosted their target price on shares of OptimizeRx from $14.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.81.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.